当前位置: 首页 >> 检索结果
386. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
作者: Nirosen Vijiaratnam.;Christine Girges.;Grace Auld.;Rachel McComish.;Alexa King.;Simon S Skene.;Steve Hibbert.;Alan Wong.;Sabina Melander.;Rachel Gibson.;Helen Matthews.;John Dickson.;Camille Carroll.;Abigail Patrick.;Jemma Inches.;Monty Silverdale.;Bethan Blackledge.;Jessica Whiston.;Michele Hu.;Jessica Welch.;Gordon Duncan.;Katie Power.;Sarah Gallen.;Jacqueline Kerr.;K Ray Chaudhuri.;Lucia Batzu.;Silvia Rota.;Edwin Jabbari.;Huw Morris.;Patricia Limousin.;Nigel Greig.;Yazhou Li.;Vincenzo Libri.;Sonia Gandhi.;Dilan Athauda.;Kashfia Chowdhury.;Tom Foltynie.
来源: Lancet. 2025年405卷10479期627-636页
GLP-1 receptor agonists have neurotrophic properties in in-vitro and in-vivo models of Parkinson's disease and results of epidemiological studies and small randomised trials have suggested possible benefits for risk and progression of Parkinson's disease. We aimed to establish whether the GLP-1 receptor agonist, exenatide, could slow the rate of progression of Parkinson's disease.
392. US withdrawal from WHO: health impacts for Angola.
作者: Mauer Alexandre da Ascensão Gonçalves.;Humberto Manuel Severin de Morais.;Cristiana Libardi Miranda Furtado.;Rafael Antônio Vicente Lacerda.;Júlio César Claudino do Santos.;Howard Lopes Ribeiro.
来源: Lancet. 2025年405卷10478期539页 393. Suspected and confirmed mpox cases in DR Congo: a retrospective analysis of national epidemiological and laboratory surveillance data, 2010-23.
作者: Eugene Bangwen.;Ruth Diavita.;Elise De Vos.;Emmanuel Hasivirwe Vakaniaki.;Sabin Sabiti Nundu.;Annie Mutombo.;Felix Mulangu.;Aaron Aruna Abedi.;Emile Malembi.;Thierry Kalonji.;Cris Kacita.;Eddy Kinganda-Lusamaki.;Tony Wawina-Bokalanga.;Cécile Kremer.;Isabel Brosius.;Christophe Van Dijck.;Emmanuel Bottieau.;Koen Vercauteren.;Adrienne Amuri-Aziza.;Jean-Claude Makangara-Cigolo.;Elisabeth Muyamuna.;Elisabeth Pukuta.;Beatrice Nguete.;Didine Kaba.;Joelle Kabamba.;Christine M Hughes.;Olivier Tshiani-Mbaya.;Anne W Rimoin.;Nicole A Hoff.;Jason Kindrachuk.;Niel Hens.;Martine Peeters.;Nicola Low.;Andrea M McCollum.;Robert Shongo.;Daniel Mukadi-Bamuleka.;Jean-Jacques Muyembe-Tamfum.;Steve Ahuka-Mundeke.;Laurens Liesenborghs.;Placide Mbala-Kingebeni.
来源: Lancet. 2025年405卷10476期408-419页
DR Congo has the highest global burden of mpox, a disease caused by infection with the monkeypox virus. The incidence has risen since 1980, but recent analyses of epidemiological trends are lacking. We aimed to describe trends in suspected and confirmed mpox cases in DR Congo using epidemiological and laboratory mpox surveillance data collected from 2010 to 2023, and provide insights that can better inform the targeting and monitoring of control strategies.
394. Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
作者: Janet A Dunn.;Peter Donnelly.;Nada Elbeltagi.;Andrea Marshall.;Amy Hopkins.;Alastair M Thompson.;Riccardo Audisio.;Sarah E Pinder.;David A Cameron.;Sue Hartup.;Lesley Turner.;Annie Young.;Helen Higgins.;Eila K Watson.;Sophie Gasson.;Peter J Barrett-Lee.;Claire Hulme.;Bethany Shinkins.;Peter S Hall.;Andrew Evans.
来源: Lancet. 2025年405卷10476期396-407页
The frequency of mammographic surveillance for women after diagnosis of breast cancer varies globally. The aim of this study was to evaluate whether less than annual mammography was non-inferior in terms of breast cancer-specific survival in women aged 50 years or older.
|